

RESERVE COPY. PATENT SPECIFICATION

NO DRAWINGS

983,815

983,815



Date of Application and filing Complete Specification July 5, 1962.

No. 25884/62.

Application made in United States of America (No. 123,115) on July 11, 1961.

Application made in United States of America (No. 185,815) on April 9, 1962.

Complete Specification Published Feb. 17, 1965.

© Crown Copyright 1965.

Index at acceptance: —C2 C(2B6A2, 2B6E, 2B6G1A, 2B6G1B, 2B6G6)

Int. Cl.:—C 07 c

COMPLETE SPECIFICATION

Process for Obtaining Optical Isomers of α -methyl-3,4-dihydroxyphenylalanine

- We, MERCK & Co., INC., a corporation duly organised and existing under the laws of the State of New Jersey, United States of America, of Rahway, New Jersey, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—
- This invention relates to a process for obtaining the optical isomers of α -methyl-3,4-dihydroxyphenylalanine in substantially pure form, which term is to be understood as meaning at least 95% pure. *L*- α -methyl-3,4-dihydroxyphenylalanine is an important new antihypertensive drug. The *D* form, while completely inactive as a hypotensive agent, is found to have the same toxicity as the *L* form. It is, therefore, important that the *D* form be separated since it contributes nothing to the antihypertensive effect. The antihypertensive activity of this compound is all in the *L* form.
- It has been found possible to selectively crystallize each enantiomorph in turn in substantially pure form from an aqueous solution of the racemic α -methyl-3,4-dihydroxyphenylalanine by forming a supersaturated solution and contacting it with seed crystals of the desired enantiomorph. The formation of the supersaturated solution can be carried out in the presence of the seed, or the supersaturated solution can be later seeded. The steps of forming and contacting with seed can thus be simultaneous or successive as conditions necessitate.
- The present invention provides a process for the preparation of the optical isomers of α -methyl-3,4-dihydroxy-phenylalanine in substantially pure form, which comprises
- contacting a supersaturated aqueous solution of the racemic mixture of the said alanine compound in a polar solvent with the crystalline seed of the desired isomer, the solution containing 0 to 90% of the alanine compound in the form of the amine salt of a water-soluble non-amphoteric acid.
- The supersaturated solution is preferably formed by preparing a substantially saturated solution of the racemic mixture in an aqueous solution of the water-soluble non-amphoteric acid, that acid being one whose acid anhydride is easily volatilized from its aqueous solution, e.g. sulphur dioxide, separating the excess of the racemic mixture and volatilizing a portion of the acidic anhydride.
- After one enantiomorph has been separated, the mother liquor, with or without increase in the supersaturation, may be brought into contact with the other enantiomorph.
- The operation can be carried out continuously. In one such method the mother liquor from the second crystallization above is recycled into the step of dissolving the racemate and the crystallized enantiomorphs are withdrawn from each crystallization continuously or intermittently. In another, the racemate is dissolved in an aqueous solution usually containing some acid, dividing the solution into two equal parts, forming a supersaturated solution of the above description with each part, contacting one such supersaturated solution with the *D* enantiomorph and the other with the *L* enantiomorph, and recycling the mother liquors to the dissolving step, the crystallized enantiomorphs being isolated from the slurries continuously or intermittently.
- Excesses of one enantiomorph may occur because of removal of some of the other from the solution in a prior crystallization before recycling the mother liquor. Although no

[Price 4s. 6d.]

one crystallization separates all of a specific isomer, by isolating the *L* form and the *D* form separately in this manner with the addition of makeup racemate between each isolation or each such pair of isolations, in order to keep the solution saturated or nearly saturated in order to facilitate the formation of supersaturated solutions, it is possible to approach complete isolation of all the *L* form.

5 The salt-forming acids which may be used include any non-amphoteric water-soluble acid. Those acids which have at least one acidic hydrogen with an ionization constant greater than 10^{-3} and which are nonoxidizing are preferred. Because of the sensitivity of the hydroxyls of this compound to oxidation to form quinoid structures, it is preferred that the acid be nonoxidizing. Thus, the term "non-oxidizing" is intended to describe an acid to which these hydroxyls are inert at the temperature and concentration used. At low temperatures and good dilution, acids such as nitric acid, which are otherwise regarded as oxidizing can be inert. The minimum ionization constant is preferable in order to provide sufficiently strong acid to form readily the phenylalanine salts when more than very small amounts of acid are used, the acid thus adding to the amount of said phenylalanine in solution. When only small or trace amounts of acid are used for the sole purpose of keeping the solution non-alkaline, any water-soluble acid is usable. In the case of poly-basic acids, only this ionizable hydrogens with a K_a greater than 10^{-3} are of importance when large proportions of acid are used. Preferred acids include hydrochloric acid, hydrobromic acid, sulphuric acid, sulphurous acid, monochloroacetic acid, dichloroacetic acid, trichloroacetic acid, phosphorous acid and phosphoric acid. Other acids such as acetic, dilute nitric, and perchloric can also be used but are preferably avoided because of either weak acid strength, which reduces the amount dissolved, or their oxidizing character. The acids should be nonamphoteric. Thus, amino acids are not advisable because of the zwitterion character of their neutral form. Their free carboxy form requires other acidic hydrogen ions to neutralize the amino groups which can just as well be used to dissolve the phenylalanine compound.

15 The first ionization constant of most polybasic acids is the only important one in the preferred embodiment since in most cases it is the only one with a K_a greater than 10^{-3} . In such cases the salt-forming acid's function is to neutralize the amino group to form the acid salts such as the bisulphite. In special cases, such as H_2SO_4 , the second acidic hydrogen also has an ionization constant in the desired range and neutral salts are obtained. The ratio of moles of amino acid in solution to equivalents of acidic hydrogen with K_a greater than 10^{-3} be such that from 0 to

90% of the amino acid is in the form of the amine salt in the final supersaturated solution from which the desired enantiomorph is to be separated. Thus, there must be some (at least 10%) of the free base present. The desired enantiomorph crystallizes as the free base leaving a mother liquor still supersaturated in the other enantiomorph. The maximum recovery of the desired enantiomorph in any one crystallization is the amount present as the free base. Above 90% of the amino acid as the amine salt, the recovery is small. Although the solubility of the free amino acid in water is less than that of the amine salt; in at least one method of operating the invention substantially all the amino acid can be present as free amine, with little or no neutralizing acid present. The solution must never be on the alkaline side in the presence of air because of decomposition, and thus usually at least a trace of a neutralising acid is preferably present to enhance stability. However, the process of the invention can be carried out in the absence of acid and, if air is excluded, even on the alkaline side, using salts of the carboxyl functional group. It is, however, easier to work at neutral pH or preferably with at least a trace of acid.

The process of this invention is carried out in solution in an aqueous polar solvent, by which is meant a solvent containing at least 10% water by volume. The solvent can incorporate any water miscible polar solvent, e.g. a lower alcohol (methanol, ethanol, sec-butanol) dioxane or acetone. With solvents other than the alcohols, water is needed to help form the dissolving acid when SO_2 is used to dissolve the amino acid.

The formation of supersaturated solutions in our invention can be carried out in several different ways. One of the most common ways is by use of change of solubility with temperature. Thus, a saturated solution is formed at one temperature (e.g., 30–45° C) and cooled in the presence of the seeding crystals to a lower temperature (e.g., below 25° C.) This procedure, using these temperature ranges, gives very excellent results provided the amino acid is in the proper allotropic form. Racemic α -methyl-3,4-dihydroxy-phenylalanine has been found to possess several different allotropic crystal forms. These forms differ in their solubility gradient with temperature. One particular form, found to have a good temperature gradient, is characterised by X-ray peaks (2θ copper $K\alpha$) at 9°, 11°, and 23°. This form (IIA), however, is unstable and changes into the stable form (I) in contact with water, even at room temperature. While the change is slow at low temperature, it becomes faster as the temperature is raised. The stable form (I) is characterised by X-ray peaks (2θ copper $K\alpha$) at 10° and 13°. The temperature gradient of the solubility of Form I is small, below 50° C., but becomes

70

75

80

85

90

95

100

105

110

115

120

125

130

mu
tur
rac
anc
sol
rai
sta
fo
wl
at
re

tv
a
li
r
t
t
i

25

30

35

40

45

5

much larger, surprisingly at higher temperatures. Thus, it is possible to dissolve the racemic material at temperatures between 60° and 100° C. and to form the supersaturated solution by cooling to temperatures in the range of 5 to 40° C. Since Form I is the stable form to which the other are transformed, this mode of operation is preferred when using the thermal method of supersaturating. It is an especially preferred method of resolving α -methylDOPA continuously.

In general, the greater the difference between the temperature of forming the saturated solution and the temperature of crystallization, the greater the tendency for racemate to precipitate. It is therefore, necessary to keep the temperature differential between these two operations as low as practical while maintaining a satisfactory rate of crystallization. A differential of at least 10° C. is necessary. The difference between the dissolving and crystallizing temperatures should not exceed 60° C. since beyond that differential racemic material tends to precipitate. The stable form (I), although having a comparatively flat temperature solubility curve at low temperatures, can thus be used in the temperature differential method by using higher temperatures, up to 100°.

The preferred temperature differential procedure, in general, is to make up a saturated solution of the racemate at 60–100° C., preferably at about 75° C. in water containing a small amount (e.g., less than 0.2 equivalents per mole of alanine) of an acid such as hydrochloric acid or sulphurous acid to get a solution of α -methylDOPA having from 0 to 20% of the amino acid in the salt form. The ratio of amino acid salt to amino acid is conveniently controlled by adding excess of phenylalanine compound to a given amount of acid. Preferably, only a trace of acid, usually sulphurous, is present for stability. The undissolved racemate is filtered and the filtrate automatically contains amino acid plus amino acid hydrochloride or bisulphite dissolved in the solution. The filtrate is seeded with crystals of the desired enantiomorph. The seeded solution is then cooled to 5 to 40° C., preferably to about 35° C.

While the foregoing is the preferred method of using temperature differences to form a supersaturated solution, the process can also be used with lower dissolving and crystallizing temperatures. Thus, the racemate may be dissolved at 35° C. and cooled below 20° C. Because of the flat solubility gradient in this range such operations are not as efficient as the use of the preferred ranges, especially when low amounts of acid are present.

The cooled seeded solution, which is either saturated or still somewhat supersaturated in the desired enantiomorph depending on the aging time and still supersaturated with the other enantiomorph, is filtered to give a 30–

50% recovery of one of the enantiomorphs at purities ranging from 95–100%. Usage of seed crystals of the desired enantiomorph will vary with the mode of operation. Preferably at least 5 g. of seed per liter of supersaturated solution is added, usually 150 g. per liter or even more. The amount of seed crystals used is a practical matter. The upper limit is a function of the viscosity of the slurry. The amount of seed to use also depends in part on the particle size since smaller particles have more seeding area per unit weight. The seeding efficiency (i.e., the combination of the amount and the particle size) controls the rate of discharge of the supersaturation. If the amount is low or the particles are large, the rate is slow. Large amounts and small particle size increase the rate of crystallization. The slower the rate the more contamination is possible.

A second alternative method of forming a supersaturated solution is to operate at a constant temperature but to change the amount of salt-forming acid present by neutralization. This procedure is especially advantageous when the amino acid has become transformed into one of the allotropic forms having a very low temperature differential of solubility. The method consists of preparing a solution in the salt-forming acid. The latter need not, but can be, in excess, in which case the solution is not saturated and has all the amino acid as the amine salt. If it is in excess, more base is needed to form a saturated and then a supersaturated solution and thus to free some amino acid from the amine salt. It is preferable to form a saturated solution by not using excess of acid. The undissolved material is again separated and then a base is added. As the dissolving acid is neutralized, a supersaturated solution is formed. The ratio of amino acid to salt-forming acid must against be such that 0 to 90% of the α -methylDOPA is present as the amine salt of the acid. The neutralization is either carried out slowly in the presence of seed crystals of one of the enantiomorphs or the supersaturated solution thus formed is later seeded with efficient agitation. The neutralisation technique can be used either at constant temperature or in conjunction with a temperature change, although it is generally better to keep the mixture at a constant temperature in order to avoid racemate from contaminating the product. The neutralisation can be carried out with any base desired e.g., ammonium hydroxide, sodium hydroxide, lime, magnesia or potassium hydroxide, as well as the carbonates or bicarbonates of these metallic ions. When the cation forms soluble salts with both the dissolving acid and the phenyl-alanine compound, the neutralization technique can be used in the presence of seed. When insoluble salts are formed with the salt-forming acid, the supersaturated

solution must be filtered before seeding. Bases forming insoluble salts of α -methylDOPA should be avoided since they will neutralize the wrong acid and remove racemate from solution.

5 Another method of forming a supersaturated solution is by volatilization of the solvent, either by raising the temperature or by lowering the pressure, from the saturated solution. 10 This method is especially usable when the aqueous solution contains a minor amount of a polar solvent, such as methanol, which is highly volatile.

15 Another method of forming the supersaturated solution is to dissolve the amino acid in an excess of an acid which has an acid anhydride volatile from aqueous solution and to transform this into a supersaturated solution by volatilization of the acid anhydride of the 20 dissolving acid from the substantially saturated solution. An example of such an acid is sulphurous acid, whose first ionization constant, only, is about 10^{-3} . Thus, in the performance of this variation, a saturated solution 25 of the racemic amino acid as the bisulphite salt is formed by bubbling sulphur dioxide into a slurry of the phenylalanine compound or by adding an excess of α -methylDOPA to a solution of SO_2 in water. An excess of the amino acid must be used in either case in order to have at least 10% of the dissolved amino acid present in the final supersaturated solution as the free base. The undissolved material is separated and the filtrate is seeded 35 as before. The seeded filtrate is then boiled either at atmospheric pressure by heating, or under reduced pressure, or sparged with an inert gas such as nitrogen to remove some of the SO_2 , and thus form a solution supersaturated in free amino acid. Again, optically-active amino acid of excellent purity can be isolated by filtration. 40

The process is especially advantageous in its adaptability to a continuous process. One 45 advantage is the ease with which the process is controlled in a continuous operation. Another is that, unlike the neutralization technique, there is no build-up of inorganic salts in the recycling mother liquor. However, for economic reasons the thermal method is preferred. 50

A very important advantage of the entire invention, whether batch or continuous but especially in a continuous process, is the purity 55 of the enantiomorph recovered. Whether operated in batches or continuously the process of this invention is remarkable in a yielding substantially pure isomer, (i.e., containing over 97% of one enantiomorph over the other and usually approaching 100%). No other simple direct process reported to be used with other compounds gives such complete resolution in the cases reported and no other continuous resolution is described. 60

65 A continuous process is carried out by run-

ing a saturated or nearly saturated solution of α -methylDOPA in non-alkaline aqueous solution into separate crystallizing vessels containing seed enantiomorphs and forming supersaturated solutions continuously in the 70 presence of the seed of each enantiomorph, which then crystallizes out in part. The separate crystallizations of each enantiomorph can be carried out in series or in parallel. When the crystallizations are carried out in series, 75 the mother liquor from the first such crystallization is continuously run into the next and its mother liquor is continuously recycled to a dissolving vessel feeding saturated solution into the crystallizing vessels. When the crystallizations are run in parallel, the saturated solution stream is divided into two parts, each going to one of the crystallizers, and the mother liquors are reunited and recycled to the dissolving step. Additional racemate is 80 regularly charged to the dissolving vessel to keep its output saturated by keeping solid racemate present at all times. It is possible to effect the complete resolution of the racemic amino acid into its enantiomorphs by this technique. 85

The continuous character of this process is dependent on control of the rates of transferring the respectively solutions to each successive vessel in the circuit so as to maintain constantly in each crystallizer the proper conditions for crystallization of the seeded enantiomorph. The dissolving vessel is held at the proper temperature if a temperature technique for forming the supersaturated solution is being employed, or treated with SO_2 , if the volatile acid anhydride technique is used, at a controlled rate. More racemate is charged intermittently to keep a solid phase always present in the dissolving vessel. The saturated solution is withdrawn at a controlled rate through a filter intake (to prevent solid racemate from being transported) and is run into the first seeded crystallizing vessel. In the crystallizer, the supersaturated solution is 100 continuously formed in the presence of the seed crystals (by maintaining the temperature at the right range, continuously adding a neutralizing base, sparging with an inert gas, maintaining a lower pressure, etc., depending on the technique being used). 105

In the series technique, the mother liquor (which is now supersaturated in one enantiomorph but not in the other) is continuously withdrawn again through a filtering intake to the second crystallizing vessel, seeded with the other enantiomorph. The second crystallizer feeds its mother liquor similarly back to the dissolving vessel and the rate of each such transfer is carefully controlled to form a balanced system. In order to make sure that substantially all the second enantiomorph in excess of a racemic mixture is recovered in the second crystallizer, it is preferred that an additional but smaller amount of SO_2 be 120 125 130

sparged also from this crystallizer or, in the case of the temperature differential method, that the second crystallizer be at a slightly lower temperature, but this is not absolutely necessary for recovery of some of the second enantiomorph. Each crystallizing vessel is fitted with a slurry removal line and the crystallized enantiomorphs are removed regularly to prevent the slurry from becoming too thick. The slurries thus removed are filtered and the filtrates are either returned to the vessel from which the slurry was withdrawn or to the dissolver.

In the parallel technique, the saturated solution is divided and continuously run into separate crystallizing vessels. The slurry of crystallized enantiomorph is kept agitated and overflow is run through a filter. The mother liquors are recombined and recycled to the dissolving vessel.

The invention can be illustrated by the following examples:

EXAMPLE 1

37 g. of racemic α -methyl-3,4-dihydroxyphenylalanine is slurried at 35° C. in 100 cc. of 1.0N hydrochloric acid. The excess of solids is filtered off, leaving a saturated solution containing 34.6 g. of racemic amino acid of which about 61% is present as the hydrochloride. The solution is then seeded at 35° C. with 7 g. of hydrated L- α -methyl-3,4-dihydroxyphenylalanine (6.2 g. of anhydrous material). The mixture is then cooled to 20° C. in 30 minutes and aged for one hour at 20° C. The separated material is isolated by filtration, washed twice with 10 cc. of cold water and dried *in vacuo*. The yield of product is 14.1 g. of L- α -methyl-3,4-dihydroxyphenylalanine in the form of a sesquihydrate of 100% purity as determined by the rotation of the copper complex.

A portion of the mother liquors from the preceding step (45 ml.) contain 3.65 g. of hydrochloric acid and 10.4 g. of α -methyl-3,4-dihydroxyphenylalanine in which there is a 61% excess of D-form. The mother liquor is heated to 35° C. and stirred with 2.4 g. of racemate. Excess of solids is removed by filtration leaving a filtrate solution containing about 12.2 g. of α -methylDOPA consisting of 67% hydrochloride. The filtrate is seeded at 35° C. with 2.7 g. of hydrated D- α -methyl-3,4-dihydroxyphenylalanine (2.4 g. of anhydrous). The mixture is then cooled to 20° C. over 30 minutes and aged one hour at 20° C. The precipitated material is isolated by filtration, washed twice with 5 cc. of cold water and dried *in vacuo*. A total of 5.5 g. of D- α -methyl-3,4-dihydroxyphenylalanine in the form of a sesquihydrate of 100% purity is obtained. The mother liquors contain the racemic amino acid with only negligible excess of either enantiomorph. These mother liquors are then recycled in the above process

by being used as the acid solution to make up the original reaction mixture.

EXAMPLE 2

10 g. of DL- α -methyl-3,4-dihydroxyphenylalanine [crystalline form 2A characterized by X-ray peaks (2 θ copper K α) at 9°, 11° and 23°] is added to 50 cc. of 0.5N hydrochloric acid solution at 35° C. The resultant suspension is agitated for 30 minutes at 35° C. The undissolved solids are filtered off and, after drying, weigh 0.22 grams. Filtrate and slurry temperature are held at 35° C. during the filtration. 1.5 Grams of L- α -methyl-3,4-dihydroxyphenylalanine are added to the filtrate which is still at 35° C. The seeded filtrate is then cooled to 20° C. at a rate of 1/2° C. per minute, aged for one hour and filtered. The wet cake weighs 4.11 grams (2.93 grams after drying at 40° C). The product is the sesquihydrate and the specific rotation, at a wave length of light of 589 m μ , of the copper salt is +170°. The yield of isomer is 26%.

EXAMPLE 3

48 g. of DL- α -methyl-3,4-dihydroxyphenylalanine [form I, characterized by X-ray peaks (2 θ copper K α) at 10° and 13°] is slurried in 100 cc. of 2.0N hydrochloric acid at 25° C. for one hour. The undissolved solids are filtered off and dried. Dry weight of these solids is 0.90 grams. 8.0 Grams of L- α -methyl-3,4-dihydroxyphenylalanine seed are added to the filtrate. 40 cc. of 2N sodium hydroxide are added to the filtrate at a rate of 1/2 cc. per minute. Temperature is maintained at 25° C. The suspension is aged for one hour at 25° C. and then filtered. Weight of the dry product (including seed) is 18.5 grams. The product is L- α -methyl-3,4-dihydroxyphenylalanine sesquihydrate and the specific rotation, at a wave length of light of 589 m μ , of its copper salt is +170°. Yield of isomer is 39%.

EXAMPLE 4

35 g. of DL- α -methyl-3,4-dihydroxyphenylalanine is slurried in 200 cc. of 0.46 molar sulphur dioxide aqueous solution at 24° C. After 70 minutes, the slurry is pressure filtered (using nitrogen for driving force). Weight of the dry undissolved solids is 10.8 grams. 210 cc. (total=214 cc.) of the filtrate and 12.6 grams of D- α -methyl-3,4-dihydroxyphenylalanine are charged to a 500 cc. Morton flask equipped with agitator and nitrogen inlet tubes. With agitator turning at 420 r.p.m., 0.42 ft³ of nitrogen is fed through a wet test meter and then through the crystallizer flask over a 35-minute period. The slurry is aged for one hour at 24° C. and then pressure filtered (using nitrogen for driving force). The product weight (including seed) is 14.6 grams. The mother liquors are titrated with sodium hydroxide to the blue end point of

brom cresol green. The sulphur dioxide content is assumed equal to the caustic solution used. Sulphur dioxide concentration by this technique is 0.28 M. The product is D- α -methyl-3,4-dihydroxyphenylalanine sesquihydrate and the specific rotation of the copper salt is $+170$ — 172° @589 m μ . The yield of D isomer is 17%.

EXAMPLE 5

The apparatus used for continuous crystallization consists of three 3-litre Pyrex glass resin kettles equipped with 4 glass baffles and a 4 bladed turbine impeller ("Pyrex is a trade mark). Each vessel is fitted with an internal filter (5/8" OD $\times$ 4" long) of medium porosity Pyrex. Use of this filter permits operation at any desired suspended solids concentration. A withdrawal line for slurry removal is also included in each crystallizer (i.e., in two of the vessels). Temperature control is by immersing the vessels in a thermostatically controlled bath. Each vessel is equipped with a thermometer for temperature measurement. Solutions are pumped from one vessel to the other in a closed circuit using peristaltic pumps and rubber tubing. Nitrogen is supplied to the crystallizers through rotameters. The dissolver kettle is fitted with a

rotameter for measurement of sulphur dioxide addition.

Operation of a typical run is described below. Each vessel is charged with the liquor in that vessel from the previous run. Water bath temperature is adjusted to 42° C. to give an internal vessel temperature of 40° C. 94.3 g. of L seed are added to the L crystallizer, 98.4 g. of D seed to the D crystallizer and 458 g. of α -methyl-3,4-dihydroxyphenylalanine which had been filtered from the contents of the dissolver in the previous run, to the dissolver. The peristaltic pumps are started and adjusted to deliver 50 cc/minute. Sulphur dioxide is fed to dissolver at 1 liter/minute. Nitrogen is sparged through the D crystallizer at 4.8 liters/minute and through the L crystallizer at .96 liter/minute. 30 g. of DL- α -methyl-3,4-dihydroxyphenylalanine is added to the dissolver each half hour. Samples are withdrawn from each vessel at 1/2 hour intervals and assayed for sulphur dioxide content by caustic titration to the blue end point of brom cresol green and for α -methylDOPA content by ultraviolet absorption at 281 m μ in a Beckman spectrophotometer. These values are reasonably constant and may be summarized as follows:

	SO ₂ Concentration (moles/liter)	α -MethylDOPA Concentration (moles/liter)
Dissolver	0.63	0.58
D-Crystallizer	0.30	.515
L-Crystallizer	0.25	.47

After operating at these conditions for 6 hours, the run is stopped. The contents of each vessel are filtered. 258 g. of D isomer (including seed) are recovered from the D crystallizer, 267 g. of L isomer from the L crystallizer and 359 g. of DL crystal from the Dissolver. The isomers are the sesquihydrates. The rotation of the copper salt of the L isomer is $+170$ — 172° , a 589 m μ and of the D isomer is $+170$ — 172° a 589 m μ . The productivity of L-isomer per 1.5 liter of crystallizing capacity is 26 grams/hour. The yield is 97.4%.

In starting up the continuous system for the initial run, the dissolver vessel is charged with 3 litres of water and SO₂ is run in at the rate of 1.8 liters/minute. About 1 kg. of racemate is added. When the SO₂ content is 0.64M, the transfer of saturated solution through the internal filter to the D crystallizer is begun at 50 cc/minute. Water is then charged to the dissolver at the same rate to maintain a constant volume. Every half-hour 28 g. more racemate is also charged to the dissolver.

When the D crystallizer vessel contains 1200 cc., a stream of nitrogen at 4.8 liters/minute is begun. A charge of 100 g. of D- α -methylDOPA is added. When the D crys-

tallizer contains 1500 cc., the withdrawal of mother liquor at 50 cc/minute through the internal filter is begun, this first mother liquor being pumped to the L-crystallizer.

When the L crystallizer contains 1200 cc. of solution, 100 g. of L- α -methylDOPA is added and sparging with nitrogen at the rate of 0.96 liters/minute is begun. When the L-crystallizer contains 1500 cc. the withdrawal of the mother liquor through the internal filter at 50 cc./minute is begun. This second mother liquor is charged to the dissolver vessel and the addition of make-up water is ceased. The system is then at the continuous phase, to be used as described above.

EXAMPLE 6

The apparatus consists of three 3-liter resin kettles, three pumps, one internal porous filter, two product filters, agitators, thermometers, rubber hose, and constant temperature baths. They are set up as follows: The first kettle, the dissolver, is equipped with agitator, thermometer, bath and the internal porous filter. The line from the filter divides into two lines, each of which passes through a pump and into a different one of the other two kettles (the crystallizers). Each of the latter is likewise fitted with a thermometer, agitator and bath.

The overflow from each kettle goes into a product filter. The filtrate lines from those latter are combined and pass through a pump back to the dissolver kettle.

5 At the start, the system is charged as follows:

35 To the dissolver are charged 2,600 ml. of 0.1N hydrochloric acid and 226 gms. of *DL*- α -methyl dihydroxyphenylalanine. This slurry is heated to 35° C. with a water bath and maintained at 35° C. throughout the operation. In the crystallizers, 152.4 g. of *DL*- α -methyl dihydroxyphenylalanine is dissolved in 3100 ml. of 0.1N hydrochloric acid at 20° C. 40 The solution is filtered to insure absence of suspended particles and charged to the crystallizers—1550 ml. to the *D*-crystallizer and 1610 ml. to the *L*-crystallizer. Both vessels are held at 20° C. by a water bath during the operation. 17.7 g. of high purity *D*- α -methyl dihydroxyphenylalanine (as the hydrate) is added to the *D*-crystallizer and 17.7 gms. of the *L*-isomer (as the hydrate) to the *L*-crystallizer. 50

25 The resolving crystallization is accomplished by pumping from the dissolver through the internal porous filter, a solution of *DL*- α -methyl dihydroxyphenylalanine at a rate of 24 ml. per minute. This flow is adjusted to deliver 12 ml. per minute to each (*D* and *L*) crystallizer. From each crystallizer a slurry of the respective isomer in the crystallization liquor overflows to an enclosed product filter. From each filter at regular intervals, 35 an equal volume of *D* mother liquor and *L* mother liquor is returned to the dissolver feed funnel where the two streams are mixed and returned to the dissolving kettle.

5 During nine hours of operation, 108.2 grams of *DL*- α -methyl dihydroxyphenyl alanine (solid) are charged to the dissolver. Similarly, an additional 8.85 grams of pure *D* and *L* isomers (solids) are charged to their respective crystallizers. At the completion of 45 the run, slurries in each vessel are filtered separately and the solids and clear liquid measured and assayed. From these filtrations and the continuous product filters, there are obtained 47.75 grams of *D*-isomer (as the hydrate) and 51.8 grams of *L*-isomer (as the hydrate) representing a net gain (above the weight of seed crystals) of 21.25 grams of *D*-isomer and 24.8 grams of *L*-isomer. Optical purity of these products is determined by 50 the rotation of a solution of the aluminum complex as $[\alpha]_D = +26.3^\circ$, $[\alpha]_D = -26.2^\circ$.

Analysis of the liquors and undissolved solids from the dissolver proves an α -methyl dihydroxyphenylalanine balance of 98.5%.

60 EXAMPLE 7

15 g. of *DL*- α -methyl DOPA is slurried in 200 cc. of 0.001 N hydrochloric acid for 30 minutes at 35° C. The slurry is filtered and the filtrate is seeded with 1.75 g. of *L*- α -

65 methyl DOPA sequehydrate. The solution is cooled at 1/2° C. per minute to 20° C. and there stirred gently for one hour. The product is filtered, washed twice with 3 cc. of cold water and dried *in vacuo*. The net anhydrous product is 1.5 g. of 99% optical 70 purity.

EXAMPLE 8

2 g. of *DL*- α -methyl DOPA is dissolved in 50 cc. of distilled water by heating to 75° C. The solution is filtered and seeded with 75 0.500 grams of *L*- α -methyl DOPA sequehydrate. It is then cooled to 25° S. and aged 1.5 hours with gentle agitation. The product is filtered, washed with 4 cc. of cold water and dried *in vacuo*. The net anhydrous product obtained is 191 mg. of 100% optical 80 purity.

EXAMPLE 9

The apparatus consists of three 3L vessels, each surrounded by a heating or cooling 85 bath. Each vessel is fitted with a stirrer and an internal filter leading to an exit line. The first vessel, the dissolver, contains solid *DL*- α -methyl DOPA as well as saturated solution. Its bath is maintained at 75° C. The exit 90 line from its internal filter divides into two lines, each leading to one of the other vessels, the crystallizers, through a metering pump and a heat exchanger. The latter are maintained at 45° C. by circulation of cooling 95 water through the jacket. Each line then passes through a second filter (to prevent any racemate which might have crystallized in the heat exchangers from contaminating the crystallization) into one of the crystallizers. The 100 baths surrounding these vessels are maintained at 35° C. and each contains supersaturated solution and the seed of an enantiomorph, as described below. The exit line from the internal filter in each crystallizer 105 passes through a metering pump and then they unite to form a return line to the dissolver.

To start the experiment, the crystallizers are charged initially with solutions of racemate almost saturated at the bath temperature (35° C) but free of undissolved material. These solutions contain 0.069 equivalents of SO₂ per liter. Each crystallizer is then 110 charged with 225 grams of seed per liter of solution. One crystallizer receives seed of the *D* form and the other that of the *L* form. The dissolver is then charged with solid racemate and saturated solution containing 0.069 equivalents of SO₂ per liter and heated 115 with stirring until the solution is saturated at the dissolver temperature (75° C). This solution is then pumped through the exit lines into the crystallizer at such a rate that nominal residence time in each crystallizer is one 120 hour. At the same time the mother liquors from the crystallizers are pumped back to the dissolver at an equal rate. The pumping is continued in this circuit with discontinuous 125

addition of solid racemate to the dissolver in order to keep solid racemate present. Portions of the slurries from the crystallizers are intermittently withdrawn from each crystallizer and filtered, and the filtrate returned to the dissolver, using a line separate from the recycling line, the intake of which is inserted into the crystalliser when used. This withdrawal is often enough to keep a concentration of seed crystals of 225 g/liter present in each crystallizer.

Samples of the contents of each vessel are taken from time to time for analysis and at the conclusion a materials balance is obtained by recovering the contents of each vessel. The results are:

Concentration of α -MethylDOPA (g/liter):
 Dissolver - - - - 55-58
 D-Crystallizer - - - - 50-53
 L-Crystallizer - - - - 50-53
 Product Quality (specific rotation of Cu complex):
 D $\pm 152^\circ$ @546 m μ
 L $\pm 152^\circ$ @546 m μ
 Productivity—1-9 g/liter/hour

Material Balance:

Input
 832.0 g. DL
 301.0 g. D-seed
 301.0 g. L-seed
 Output
 429.6 g. D
 422.1 g. L
 2570.0 g. DL solids in dissolver
 221.8 g. DL in liquors
 34.9 g. lost in washes
 25.0 g. lost in sampling.
 Net Product
 128.6 g. D
 121.1 g. L

WHAT WE CLAIM IS:—

1. A process for the preparation of the optical isomers of α -methyl-3,4-dihydroxyphenylalanine in substantially pure form, which comprises contacting a supersaturated aqueous solution of the racemic mixture of the said alanine compound in a polar solvent with the crystalline seed of the desired isomer, the solution containing 0 to 90% of the alanine compound in the form of the

amine salt of a water-soluble non-amphoteric acid.

2. A process as claimed in Claim 1, in which the proportion of the crystalline seed is at least 5 g. per litre of solution, the supersaturated acid solution contains from 10% to 90% of the alanine compound in the form of the amine salt of the dissolving acid, and the acid has at least one acidic hydrogen with ionization constant greater than 10^{-3} .

3. A process as claimed in Claim 1 or 2, in which the supersaturated solution is formed by preparing a substantially saturated solution of the racemic mixture in an aqueous solution of the water-soluble non-amphoteric acid, that acid being one whose acid anhydride is easily volatilized from its aqueous solution, separating the excess of the racemic mixture and volatilizing a portion of the acidic anhydride.

4. A process as claimed in Claim 3, in which the acidic anhydride is sulphur dioxide.

5. A process as claimed in any preceding claim, in which, after one enantiomorph has been precipitated and removed, the mother liquor is seeded with a crystal of the other enantiomorph to remove that.

6. A process as claimed in Claim 5, in which the mother liquor from the second seeding is used again by being supersaturated with the racemate.

7. A process as claimed in any one of Claims 1 to 4, in which a first portion of the supersaturated solution is seeded with crystals of the L isomer, a second portion of the supersaturated solution is seeded with crystals of the D isomer, and the mother liquors from both seeding processes are mixed and recycled to the supersaturation stage.

8. A process as claimed in Claim 1, substantially as hereinbefore described with reference to the Examples.

9. Optical isomers of α -methyl-3,4-dihydroxyphenylalanine, when prepared by a process as claimed in any one of Claims 1 to 8 or its obvious chemical equivalent.

For the Applicants,
 D. YOUNG & CO.,
 Chartered Patent Agents,
 9 Staple Inn, London, W.C.1.

Leamington Spa: Printed for Her Majesty's Stationery Office by the Courier Press.—1965.
 Published at The Patent Office, 25, Southampton Buildings, London, W.C.2, from which copies may be obtained.

ERRATA

SPECIFICATION No. 983,815

Page 2, line 65, after 10^{-3} insert "is"
 Page 3, line 108, for "against" read "again"
 Page 8, line 34, for "2570.0" read "257.0"
 Page 8, line 93, for "opical" read "optical"

THE PATENT OFFICE
 9th March 1965



addition of solid racemate to the dissolver in order to keep solid racemate present. Portions of the slurries from the crystallizers are intermittently withdrawn from each crystallizer and filtered, and the filtrate returned to the dissolver, using a line separate from the recycling line, the intake of which is inserted into the crystalliser when used. This withdrawal is often enough to keep a concentration of seed crystals of 225 g/liter present in each crystallizer.

Samples of the contents of each vessel are taken from time to time for analysis and at the conclusion a materials balance is obtained by recovering the contents of each vessel. The results are:

Concentration of α -MethylDOPA (g/liter):	
Dissolver	55—58
D-Crystallizer	50—53
L-Crystallizer	50—53

Product Quality (specific rotation of Cu complex):

D	$\pm 152^\circ @ 546 \text{ m}\mu$
L	$\pm 152^\circ @ 546 \text{ m}\mu$
Productivity	1—9 g/liter/hour

Material Balance: .

Input	
832.0 g. DL	
301.0 g. D-seed	
301.0 g. L-seed	
Output	
429.6 g. D	
422.1 g. L	
2570.0 g. DL solids in dissolver	
221.8 g. DL in liquors	
34.9 g. lost in washes	
25.0 g. lost in sampling.	
Net Product	
128.6 g. D	
121.1 g. L	

WHAT WE CLAIM IS:—

1. A process for the preparation of the optical isomers of α -methyl-3,4-dihydroxyphenylalanine in substantially pure form, which comprises contacting a supersaturated aqueous solution of the racemic mixture of the said alanine compound in a polar solvent with the crystalline seed of the desired isomer, the solution containing 0 to 90% of the alanine compound in the form of the

amine salt of a water-soluble non-amphoteric acid.

2. A process as claimed in Claim 1, in which the proportion of the crystalline seed is at least 5 g. per litre of solution, the supersaturated acid solution contains from 10% to 90% of the alanine compound in the form of the amine salt of the dissolving acid, and the acid has at least one acidic hydrogen with ionization constant greater than 10^{-3} .

3. A process as claimed in Claim 1 or 2, in which the supersaturated solution is formed by preparing a substantially saturated solution of the racemic mixture in an aqueous solution of the water-soluble non-amphoteric acid, that acid being one whose acid anhydride is easily volatilized from its aqueous solution, separating the excess of the racemic mixture and volatilizing a portion of the acidic anhydride.

4. A process as claimed in Claim 3, in which the acidic anhydride is sulphur dioxide.

5. A process as claimed in any preceding claim, in which, after one enantiomorph has been precipitated and removed, the mother liquor is seeded with a crystal of the other enantiomorph to remove that.

6. A process as claimed in Claim 5, in which the mother liquor from the second seeding is used again by being supersaturated with the racemate.

7. A process as claimed in any one of Claims 1 to 4, in which a first portion of the supersaturated solution is seeded with crystals of the L isomer, a second portion of the supersaturated solution is seeded with crystals of the D isomer, and the mother liquors from both seeding processes are mixed and recycled to the supersaturation stage.

8. A process as claimed in Claim 1, substantially as hereinbefore described with reference to the Examples.

9. Optical isomers of α -methyl-3,4-dihydroxyphenylalanine, when prepared by a process as claimed in any one of Claims 1 to 8 or its obvious chemical equivalent.

For the Applicants,
D. YOUNG & CO.,
Chartered Patent Agents,
9 Staple Inn, London, W.C.1.

Leamington Spa: Printed for Her Majesty's Stationery Office by the Courier Press.—1965.
Published at The Patent Office, 25, Southampton Buildings, London, W.C.2, from which copies may be obtained.

ERRATA

SPECIFICATION No. 983,815

Page 2, line 65, after 10^{-3} insert "is"
Page 3, line 108, for "against" read "again"
Page 8, line 34, for "2570.0" read "257.0"
Page 8, line 93, for "opical" read "optical"

THE PATENT OFFICE
9th March 1965